; (ii) in subparagraph (G)— (I) in clause (i), by striking based on and inserting based on— ; (II) in clause (ii), by striking ; and at the end and inserting a semicolon; (III) in clause (iii), by striking the period and inserting ; and ; and (IV) by adding at the end the following: (iv) that include, as appropriate, participation by relevant industry, academia, professional societies, and other stakeholders. ; (iii) in subparagraph (H)— (I) by inserting and the Director of the Office of Pandemic Preparedness and Response after Security Affairs ; and (II) by inserting and medical product and supply capacity planning pursuant to subparagraph (J), including discussion of any relevant identified supply chain vulnerabilities before the period at the end; (iv) in subparagraph (I), by inserting the Director of the Office of Pandemic Preparedness and Response Policy, after Security Affairs, ; and (v) in subparagraph (J)(i), in the matter preceding subclause (I), by inserting (including ancillary medical supplies and components of medical products, such as active pharmaceutical ingredients, key starting materials, and medical device components) after supply needs ; and (C) in paragraph (7)— (i) in the matter preceding subparagraph (A), by inserting and the requirements developed pursuant to paragraph (3)(B) after subsection (d) ; (ii) by redesignating subparagraphs (E) and (F) as subparagraphs (F) and (G), respectively; and (iii) by inserting after subparagraph (D) the following: (E) include a professional judgment of anticipated budget needs for each future fiscal year accounted for in such plan to account for the full range of anticipated medical countermeasure needs and life-cycle costs to address such priorities and requirements;